Capricor Therapeutics(CAPR) - 2025 Q4 - Annual Results

Fourth Quarter 2025 and Recent Highlights ● Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026 ● Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF) ● Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits ● San Diego GMP manufacturing facility operational to support potential commercial launch ● Capricor uplisted to the Nasdaq Global Sel ...